Clinical Value of Sacubactril Valsartan in Patients with Acute Myocardial Infarction Complicated with Cardiac Insufficiency after PCI
Objective To analyze the clinical value of sacubactril valsartan in the treatment of acute myocardial infarc-tion with cardiac insufficiency and percutaneous coronary intervention(PCI).Methods 106 patients with acute myo-cardial infarction combined with cardiac insufficiency PCI admitted to Binzhou People's Hospital from June 2020 to June 2023 were selected as the study subjects.According to different treatment plans,they were divided into the con-trol group(n=53,receiving perioperative PCI treatment)and the study group(n=53,receiving sacubactril valsartan on the basis of the control group's treatment).The indexes of cardiac function and myocardial injury of two groups were compared.Results After treatment,the left ventricular ejection fraction,stroke volume in the study group were higher than those in the control group,while the left ventricular end diastolic diameter was lower than that in the control group,and the differences were statistically significant(all P<0.05).After treatment,the serum levels of hypersensitive troponin Ⅰ(0.07±0.02)ng/mL and N-terminal B-type brain natriuretic peptide precursor(1 804.71±228.09)pg/mL in the study group were lower than those in the control group,and the differences were statistically significant(t=11.395,7.754,both P<0.001).Conclusion In the treatment of patients with acute myocardial infarction complicated by PCI,sacubactril valsartan has a significant therapeutic effect,which can promote the improvement of patients'func-tional indexes and myocardial injury indexes.
万方数据
维普
